Adia Nutrition Secures Lease for First Clinic in Winter Park, Florida
29 oct. 2024 09h00 HE
|
ADIA Nutrition
WINTER PARK, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition Inc. proudly announces the signed lease for their state-of-the-art clinic, set to open in the distinguished Winter Park Medical...
Trethera Announces Presentation at the Rare Neuroimmune Disorders Symposium Annual Meeting
15 oct. 2024 11h48 HE
|
Trethera Corporation
LOS ANGELES, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Adia Nutrition Inc. Takes Major Steps Forward: Signs LOI for First Clinic and Engages Legal Expertise for Licensing
15 oct. 2024 10h00 HE
|
ADIA Nutrition
WINTER PARK, Fla., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition (OTC Pink: ADIA) is proud to announce a groundbreaking initiative in the fight against Multiple Sclerosis (MS) with the signing of...
ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion
17 sept. 2024 10h00 HE
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition Inc. (OTC Pink: ADIA) has announced the hiring of a prominent Winter Springs law firm to fortify its intellectual property...
ADIA Nutrition Appoints Dr. Richard Edwards, DO as Second Medical Director
10 sept. 2024 10h00 HE
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition (OTC Pink: ADIA) is excited to announce the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards...
Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board
05 sept. 2023 10h55 HE
|
Trethera Corporation
LOS ANGELES, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
Trethera Receives NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
14 août 2023 11h23 HE
|
Trethera Corporation
LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
Trethera Announces Appointment of Laurent Dubois to Board of Directors
15 févr. 2023 10h32 HE
|
Trethera Corporation
LOS ANGELES, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces Poster Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
24 janv. 2023 12h12 HE
|
Trethera Corporation
LOS ANGELES, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
Trethera Announces Appointment of R. Boyd Quinnell to Board of Directors
18 janv. 2023 12h37 HE
|
Trethera Corporation
LOS ANGELES, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...